75 results about "Akkermansia muciniphila" patented technology

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

The invention belongs to the field of application of probiotics, and particularly relates to application of an Akkermansia muciniphila BAA-835 bacterial strain on preparation medicines for treating or preventing obesity. C57/BL6 male SPF-level mice in a nest are randomly divided into a comparison group and a bacteria intragastric administration group, according to a check experiment, an Akkermansia muciniphila BAA-835 bacterial strain suspension intragastric administration experiment is carried out on the mice of the bacteria intragastric administration group once every day, and lasts for 5 weeks, through the experiment, weight and body fat of the mice in the bacteria intragastric administration group are reduced obviously, and by the Akkermansia muciniphila BAA-835 bacterial strain, content of subcutaneous fat of groins of the mice and content of fat beside epididymides of the mice are reduced quite effectively, and therefore, the bacterial strain can be used for treating or preventing the obesity.

The invention discloses a biomarker capable of detecting diseases. The biomarker at least comprises one of the following microbes or the combination of the following microbes: Akkermansia muciniphila, Bacteroides fragilis, Clostridium bolteae, Clostridium hathewayi, Clostridium sp.HGF2, Clostridium symbiosum, Eubacterium limosum, Lactobacillus fermentum, Lactobacillus salivarius, Ruminococcus torques, Streptococcus anginosus, Streptococcus infantis, Bacteroides stercoris, Bacteroides uniformis, Bilophila wadsworthia and Clostridiales sp.SS3/4. The invention further discloses an application of the biomarker for determining inflammatory bowel diseases. The invention also discloses a method, a system and a kit for detecting the biomarker in a tested object. According to the invention, through the research on intestinal flora, and through the high-throughput genome sequencing, the biomarker with high relativity with the inflammatory bowel diseases is screened out, and then the biomarker is utilized for accurately and efficiently detecting and diagnosing the inflammatory bowel diseases, and further used for monitoring the treatment effect for the disease.

The present invention relates to a biomarker for risk prediction or diagnosis of metabolic and inflammatory diseases, and use thereof. The biomarker is formulated to detect a group of microorganisms consisting of Akkermansia muciniphila, Bacteroides spp., Eubacterium spp., Roseburia spp., Methanobrevibacter smithii, Methanosphaera stadtmanae, Ruminococcus obeum, and Phascolarctobacterium.

The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for/representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.

The invention provides a compound preparation for increasing ratio of AKK (akkermansia muciniphila) bacteria and pathogenic bacteria in intestines as well as a preparation method and application thereof, and relates to the field of oral preparations. The compound preparation for increasing the ratio of AKK bacteria to pathogenic bacteria in the intestines is prepared from the following raw materials in percentage by mass: 21% to 64% of oligosaccharide, 21% to 44% of plant extract, 9% to 31% of fungus extract, 0.5% to 5% of sodium taurate, and 0.5% to 5% of elaeagnus angustifolia extract. The compound preparation has the advantages that the safety is good, and the intestinal flora can be effectively regulated. The preparation method of the compound preparation comprises the following stepsof mixing the oligosaccharide, the plant extract, the fungus extract, sodium taurate and the elaeagnus angustifolia extract, and grinding, so as to obtain the compound preparation. The preparation method has the advantages that the technology is simple, and the industrialized production is easy. The application of the compound preparation for increasing the ratio of AKK bacteria to pathogenic bacteria in the intestines is characterized in that the compound preparation is used for preparing the oral preparation for increasing the abundance of the AKK bacteria in the intestines, and reducing theabundance of the pathogenic bacteria.

The present invention relates to a Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and a use thereof. Specifically provided are: a composition for appetite control or prevention, improvement, alleviation or treatment of metabolic diseases, containing, as an active ingredient, the strain, a culture liquid thereof and the like, or a B2UM07 protein isolated therefrom; a use of the composition for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases; and a method for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases by using the composition. Therefore, the present invention exhibits effects of weight loss and glucose homeostasis control, from among anti-obesity effects, and influence on brown fat and secretion of an appetite control hormone secretion.

The invention discloses an application of Akkermansia Muciniphila in the preparation of drugs for preventing depression or health products. In vivo pharmacodynamic studies are performed on the effectsof Akkermansia Muciniphila bacteria in depression and anti-depression; results show that the Akkermansia Muciniphila abundance in the intestinal tracts of depression patients is obviously reduced; and animal experiment results show that the Akkermansia Muciniphila abundance in the intestinal tracts of mice is obviously reduced. The Akkermansia Muciniphila bacteria are transplanted to a depressionmouse model, and experiments show that the transplantation of the Akkermansia Muciniphila bacteria can increase the movement distances of the mice and reduce the dead time of tail suspension tests and forced swimming tests, and the depression states of the mice can be significantly alleviated, so that the Akkermansia Muciniphila bacteria show good anti-depression curative effects and has no side-effects yet.

The present disclosure relates to an Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease and uses thereof. Since the Akkermansia muciniphila strain, the intestinal microorganism of the present disclosure, shows an effect of improving movement control and cognitive abilities as well as memory in an animal model having a degenerative brain disease such as Parkinson's disease and Alzheimer's disease, it can be useful in the prevention or treatment of brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc. In addition, it was confirmed in the present disclosure that compared to the Akkermansia muciniphila strain cultured in a mucin-containing medium, that cultured in a mucin-free medium showed a remarkable effect of improving hyperlipidemia, fatty liver, obesity, and hyperglycemia induced in a mouse model by high-fat diet when administered orally (in vivo). Accordingly, the present disclosure is expected to be very useful in relevant industries as a particular composition of culture medium and an optimized obligatory anaerobic culture method have been developed through the present disclosure.

The present invention relates to pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of pasteurized Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

The invention discloses a new Akkermansia muciniphila 139 strain. The strain is collected in the China General Microbiological Culture Collection Center with a collection number of CGMCC No. 16758, and a collection date is November 21st, 2018. The invention also discloses a purpose of the strain. Through separation and authentication, a new strain, i.e., the Akkermansia muciniphila 139, of Akkermansia muciniphila is obtained, the strain can carry out fermentation in vitro to generate a great quantity of short chain fatty acids, and the intestinal health of a host can be maintained. The fermentation in vitro of supernatant can induce the differentiation of mice lymphocyte regulative T cells, and the immunologic function of the host is enhanced. In addition, the bacteria strain also can alleviate enteritis, especially DSS (dextran sulfate sodium)-induced chronic enteritis, and also has a probiotic function.

The invention provides Akkermansia muciniphila and an application thereof to preparation of an antitumor drug, and relates to the technical field of biological pharmacy. The Akkermansia muciniphila is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC. M.2020950, the preservation date is December 21, 2020, and the preservation address is No. 299 on eight road, Wuchang District, Wuhan, Hubei Province. The application refers to the application to preparation of the antitumor drug. A new strain Akkermansia muciniphila SZ of the Akkermansia muciniphila is obtained through separation, culture and identification, fermentation supernate and viable bacteria obtained through in-vitro fermentation of the strain have the effect of remarkably inhibiting tumor cell proliferation, the strain can be used for preparing products or drugs for diagnosing, preventing and/or treating tumors, the preparation cost is low, the preparation efficiency is high, the side effect is small, and good industrial application prospects are realized.

The invention provides a microbial composition with a weight losing effect. The microbial composition is prepared from lactobacillus gasseri and ackermansiella muciniphila, wherein the lactobacillus gasseri and the ackermansiella muciniphila are added into the microbial composition; the ratio of the viable count of the lactobacillus gasseri to the viable count of the mucophilic protein-ackermania is (2: 3)-(3: 2). By means of the probiotic composition containing lactobacillus gasseri and mucoprotein-ackermania in a specific ratio and specific content, the condition of abnormal body weight caused by metabolic diseases can be improved.

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from Akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet. In addition, in the present invention, a fermented food itself, prepared by adding Akkermansia muciniphila, can be used for the purpose of preventing or alleviating a metabolic disease occurring or exacerbated due to a high fat diet.

The present invention pertains to a composition comprising garcinol individually or in combination with forskolin for modifying the gut microbial diversity. More specifically, the invention relates to the use of composition comprising garcinol and forskolin for decreasing the Firmicutes/Bacteroidetes ratio and increasing the count of beneficial microbe, Akkermansia muciniphila.

The invention brings forward biomarkers for end-stage renal disease and an application thereof. The biomarkers for end-stage renal disease are Akkermansia muciniphila, Alistipes finegoldii, Alistipesshahii, Bacteroides fibrobacter, Bacteroides fragilis, Bifidobacterium dentium, Clostridium difficile, Clostridium saccharolyticum, Desulfovibrio Vulgaris, Eggerthella lenta, Enterococcus faecalis, Enterococcus faecium, Flavonifractor plautii, Fusobacterium nucleatum, butyric acid-producing enterobacteriaceae, Lactobacillus amylovorus, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus plantarum, Streptococcus infantarius, Streptococcus thermophilus, butyrate-producing bacteria, Eubacterium rectal and Faecalibacterium prausnitzi. Whether a subject suffers from or is susceptible to end-stage renal disease can be effectively determined by determining these microbial markers in the intestinal flora of the subject.

The invention provides application of akkermansia muciniphila or prevotella copri to preparation of drugs for enhancing the anti-tumor immune function of CD4+T cells and/or CD8+T cells and/or for enhancing the anti-tumor immune function of CD8+T cells in the tumor microenvironment. The akkermansia muciniphila or the prevotella copri can significantly inhibit PD-1 expressed by systematic CD4+T cells and/or CD8+T cells, can also promote infiltrating and/or accumulating of the CD8+T cells in the tumor microenvironment, inhibits expression of PD-1 molecules, and significantly inhibits tumor growth.

The invention relates to the field of biological preparations, and specifically discloses applications of Akkermansia muciniphila in preparing microecological preparations for treating or preventing avian influenza virus infection. Intervention is performed on mice with pasteurized Akkermansia muciniphila; and through the infection of H7N9 influenza viruses, aspects such as the survival rates, weight changes, virus content in lungs, lung pathological changes and lung cytokine levels of the mice in each group can be assessed. Through the indication of results, the pasteurized Akkermansia muciniphila can significantly improve weight loss and lung tissue damage caused by H7N9 influenza virus infection, inhibit the reproduction of lung viruses and significantly enhance the survival rates of the mice infected with the H7N9 influenza viruses; prepared microecological preparations are safe and have no toxic and side effects, and are more convenient to store compared with other live bacteria microecological preparations; and thus, important technical support can be provided for the development of novel anti-influenza preparations.

Disclosed are compositions containing garcinol for the therapeutic management of obesity. More specifically, the invention relates to the use of garcinol for a) maintaining energy balance in mammalian adipose cellular systems b) management of hypercholesterolemia and c) reducing weight gain in mammals. The modification of gut microbiota and the increase of beneficial microbe, Akkermansia muciniphila by garcinol are also disclosed.

The invention relates to the field of akkermansia muciniphila compositions, and provides a medicine composition. The medicine composition comprises Akkermansia muciniphila and metformin, wherein on the basis of the mass of the medicine composition, the number of the live akkermansia muciniphila is 10<6>-10<14> CFU/g, and the content of the metformin is 20-60%.

The invention relates to a composition for regulating the abundance of Akkermansia muciniphila in the intestinal tract. The composition is composed of L-valine and preparation auxiliary materials. Theeffect of preventing the reduction of the abundance of the Akkermansia muciniphila in the intestinal tract is achieved by supplementing a certain amount of L-valine to the intestinal tract. Generally, the content of the Akkermansia muciniphila in the body of a patient suffering from inflammatory bowel disease and obesity can be reduced, and the composition can restore the abundance of the Akkermansia muciniphila in the mode of supplementing the L-valine, so that the metabolic state is improved. The composition can serve as food or a health care product or a medicine for restoring the abundance of the Akkermansia muciniphila.